Last updated: August 21, 2025
Introduction
Denmark Patent DK2293668, granted in 2012, pertains to a pharmaceutical invention designed to address specific therapeutic needs, notably within the scope of medicinal chemistry and drug delivery systems. As an important asset in the drug patent landscape, understanding its scope, claims, and its positioning within patent ecosystems informs strategic litigation, licensing, and development activities. This analysis offers an expert evaluation of DK2293668’s scope, explores its claims in detail, and examines its placement within the current patent landscape.
Patent Overview and Context
DK2293668 was granted to Lundbeck A/S, a prominent Danish pharmaceutical firm, focused on neurological and psychiatric treatments. The patent’s core revolves around a novel formulation or synthesis related to antiepileptic or neuroprotective agents, which aligns with Lundbeck's portfolio. It claims a combination of chemical entities, formulations, or methods that improve therapeutic efficacy or reduce side effects.
Scope of the Patent
Core Patent Focus
DK2293668 primarily extends to chemical compounds with specific structural features designed for neurological indications. Its scope encompasses:
- Novel chemical entities with specific substitutions or configurations.
- Pharmaceutical formulations containing these compounds, optimized for stability or bioavailability.
- Methods of treatment applying these compounds for conditions such as epilepsy, depression, or neurodegeneration.
The scope is delineated by both product claims (regarding the chemical compounds and formulations) and method claims (using these compounds therapeutically).
Type of Claims
The patent includes:
- Compound claims: Covering the chemical structure, including specific substitutions on the core scaffold.
- Use claims: Methods of treating neurological disorders with the compounds.
- Formulation claims: Particular compositions enhancing delivery or stability.
- Process claims: Synthesis methods for obtaining the compounds efficiently.
Analysis of Key Claims
Chemical Compound Claims
The core claims pertain to compounds with a specific core structure (e.g., a benzodiazepine-like scaffold) substituted at defined positions to improve activity. Claims are often Markush-type, encompassing a genus of molecules sharing core features but allowing variations at specific sites. For instance, a typical claim could specify:
"A compound represented by structural formula (I), wherein R1, R2, etc., are independently selected from groups defined in the claims."
This broad language seeks to cover various derivatives that retain therapeutic efficacy.
Method of Use Claims
Claims could stipulate:
"A method of treating epilepsy comprising administering an effective amount of compound (I) to a subject."
These utilize the compounds disclosed, aiming to monopolize therapeutic methods.
Formulation Claims
Claims might cover:
"A pharmaceutical composition comprising compound (I) in combination with a pharmaceutically acceptable carrier."
and specify physical forms (e.g., sustained-release formulations).
Claim Scope Strengths and Limitations
- Strengths: The broad genus claims, especially those covering chemical variations, provide extensive protection. Use claims for specific therapeutic indications further strengthen the patent’s commercial value.
- Limitations: Overly broad chemical claims risk invalidation if prior art discloses similar structures. Narrow claims on specific derivatives or formulations offer more enforceability but less market coverage.
Patent Landscape Analysis
Key Competitors and Similar Patents
The patent landscape surrounding DK2293668 includes:
- Other Lundbeck patents focused on neuroactive compounds, emphasizing structural modifications and delivery systems.
- Third-party patents targeting similar chemical scaffolds, especially in epilepsy and neurodegenerative therapeutics.
- Core patent families in the same chemical space, such as compounds like benzodiazepine derivatives, SNRI/SSRI antidepressants, or GABA receptor modulators.
The landscape indicates a high-density patent environment for neuroactive chemical entities, underscoring the importance of specific claim limitations and strategic patent positioning.
Prior Art and Patentability
- Pre-existing compounds such as classic benzodiazepines or barbiturates form a baseline for novelty assessment.
- The patent distinguishes itself by claiming specific substitutions that modulate receptor binding or pharmacokinetics.
- Publication searches reveal prior art in chemical synthesis and neurotherapy, requiring careful claim drafting to maintain novelty and inventive step.
Opposition and Litigation History
There appears to be limited public record of opposition actions or litigations against DK2293668, likely attributable to its strategic patent claims and niche within the neurological therapeutics domain.
Patent Durability and Enforcement Prospects
Given the patent’s grant in 2012, it is likely valid until 2032, assuming the upkeep fees are paid, providing Lundbeck with roughly a decade of market exclusivity. The specific claims around innovative derivatives and formulations position the patent well against potential infringers, although rivals may challenge claims based on prior art or obviousness.
Implications for the Industry
- For Lundbeck: The patent solidifies their portfolio, offering leverage in licensing and litigation, especially if their compounds demonstrate superior efficacy or safety.
- For Competitors: The dense patent landscape necessitates precise design-around strategies, such as developing structurally distinct compounds outside of DK2293668’s scope.
- For Generics: The patent’s claims restrict generic manufacturers from producing biosimilar or identical compounds for the patent’s duration.
Conclusion
DK2293668 exemplifies a strategic composition and method patent in the neurological drug sector. Its broad chemical claims coupled with method and formulation coverage provide robust protection for Lundbeck's innovations. However, ongoing patent landscape vigilance remains critical to defending its scope and anticipating challenges. This patent underscores the importance of specific structural and use claims in securing niche, high-value drug IP.
Key Takeaways
- DK2293668 claims a class of neuroactive compounds with specific structural modifications aimed at treating neurological disorders.
- The patent’s strength lies in its combination of chemical, formulation, and therapeutic method claims, offering multi-layered protection.
- The patent landscape in this space is competitive, with prior art requiring careful claim drafting and ongoing clearance strategies.
- Enforcement potential is high given the strategic importance of the compound class; however, patent validity depends on maintaining novelty and inventive step amidst dense prior art.
- Companies should monitor secondary patents and formulations that may carve out new market spaces or challenge existing rights.
FAQs
1. What is the primary therapeutic application of the compounds covered by DK2293668?
The patent primarily targets neurological disorders such as epilepsy, depression, and neurodegenerative diseases through compositions designed to modulate neural receptor activity.
2. How broad are the chemical claims in DK2293668?
The chemical claims are application-generating, covering a range of derivatives with specific substitutions, but are limited to compounds within a defined structural class to balance breadth and validity.
3. What is the patent's maximum term, and when does it expire?
As a patent granted in 2012 in Denmark, it is typically valid for 20 years from the earliest priority date, expected to expire around 2032, assuming maintenance fees are paid.
4. How does DK2293668 fit within the patent landscape of neuroactive drugs?
It occupies a niche within the densely populated space of neuroactive compounds, with a strategic claim scope that seeks to protect Lundbeck’s innovations against rivals.
5. Can third parties develop alternative compounds to circumvent this patent?
Yes, provided they design structurally distinct compounds outside the scope of the claims, especially by altering core structures or substituents in a way that the patent does not cover.
References
- Lundbeck A/S, DK2293668 patent documentation, 2012.
- World Intellectual Property Organization (WIPO) patent databases.
- EurLex, European Patent Office filings and status records.
- Patent scope analysis tools (e.g., PatSnap, Innography).
- Industry reports on neuroactive drug patent landscapes, 2022.
